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PATHOGENESIS OF INTRACRANIAL ANEURYSMS
BRIAN V. NAHED AND MURAT GUNEL
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT.

Introduction:
Intracranial aneurysms (IA) are a common neurological problem, the rupture of which
frequently constitutes a catastrophic neurological event. While the pathogenesis is largely
unknown, it is believed that both genetic and environmental factors work in concert to
some degree within patients. Our goal was to take a comprehensive approach to
understanding the pathogenesis of IA by identifying factors leading to the formation,
growth and rupture of IA.
Methods:
Since 1994, we have recruited patients and families with IA into the Yale Brain
Aneurysm Database. Information regarding aneurysm characteristics (size, location,
number), patient characteristics (age, medical, and social history), and family history
were recorded. We analyzed this database for environmental factors associated with
aneurysmal rupture. Within the same database, we identified and analyzed kindreds with
a high IA incidence and penetrance using genome-wide linkage analysis. Collaborations
with other centers provided additional kindreds to analyze and confirm our results.
Results:
Analysis of our database revealed hypertensive patients with IA ≤ 7mm were 2.6 times
more likely to rupture (p = .01, 95% CI: 1.21, 5.53) than normotensive patients. Posterior
circulation aneurysms were 3.5 times more likely to rupture than anterior circulation
aneurysms (p = .048, 95% CI: 0.95, 19.4). Further, genome-wide linkage analysis
revealed significant linkage to a single locus, with a lod score of 4.2 at 1p34-36.
Conclusions:
We identified hypertension, young age, and posterior circulation as significant risk
factors for rupture among patients with small aneurysms (≤ 7mm). Additionally, we are
the first to map the gene responsible for IA to chromosome 1p34-26.
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CLINICAL OVERVIEW
Aneurysmal subarachnoid hemorrhage (SAH) is a serious neurosurgical
emergency with poor prognosis; approximately 12% of patients die before reaching
medical attention (1), and 40% die in hospital care (2-4). Survivors of SAH frequently
leave the hospital severely disabled requiring a lifetime of care (5, 6).
Although the majority of intracranial aneurysms (IA) do not rupture, those that do
account for around 85% of SAH (7). The incidence of SAH is 6 in 100,000 per year with
approximately 28,000 ruptures per year. Those individuals who survive the initial bleed
experience a 40% mortality rate during the first month; 25% of those who live past the
first month recover completely (8).
SAH accounts for 3% of all strokes (8), 5% of stroke deaths, and more than onequarter of potential life years are lost through stroke (9). Although the 20th century has
seen great advances in diagnosis, treatment, and prevention of complications of SAH, the
overall outcome has only modestly improved (10) leaving formidable challenges ahead
for physicians caring for these patients.
Given the devastating sequelae of SAH, surgical or endovascular intervention
prior to rupture is considered to be of paramount importance. Guidelines have been
established to assist in the decision between treatment and careful monitoring, with the
goal of prophylactically treating those aneurysms that are likely to rupture. Attempts to
identify risk factors and the pathophysiology leading to aneurysm formation and rupture
have been unsuccessful.
By studying populations in which the etiology of IA is relatively homogeneous
one can begin to resolve these complexities and reveal the basic mechanisms of
pathogenesis.

2
INTRACRANIAL ANEURYSMS
Intracranial aneurysms (IA) are characterized by abnormal localized dilatations
representing cerebral arterial wall compromise. The origin of the word aneurysm stems
from the Latin word aneurysma, which means dilatation. IA affect 5 – 10 % of the
general population (11) and represent a major public health problem. It is estimated that
2.3% of the population have undetected aneurysms (12), the majority of which will not
rupture. When they rupture, the morbidity and mortality is devastating with
approximately half resulting in immediate death.
Currently there are no reliable screening methods to identify at-risk individuals.
Therefore, clinicians resort to imaging at-risk individuals (loosely defined as having a
parent or sibling with IA) using magnetic resonance angiography (MRA) or
computerized tomography angiography (CTA). Moreover, there are no widely accepted
guidelines defining high-risk individuals.
For many years, the decision to operate on an unruptured aneurysm was based
solely on the size of the aneurysm determined by imaging studies. One large multi-center
trial suggested that IA ≥ 10 mm had a risk of rupture of 1% per year (13) with smaller
aneurysms having a much smaller risk of rupture. However, this initial data conflicted
with clinical experience in which a significant number of patients present with SAH due
to aneurysms less than 10 mm in size. Furthermore, the data contradicted a previously
published series in which aneurysms <10 mm were at risk of rupture (14).
Progress in understanding the pathogenesis of IA has been hampered by its multifactorial nature. Neither the conditions that lead to aneurysm formation nor rupture are
well understood. Instead, clinicians are left to speculate on the importance of risk factors
such as hypertension, smoking, alcohol, low body mass index, drug use and family
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history when deciding the degree of intervention. Given the large number of familial
cases and increased incidence with other genetic diseases such as adult polycystic kidney
disease (ADPKD), the genetic basis of aneurysms has been alluded to but a gene has yet
to be identified.
Recent studies suggest that both environmental and genetic factors contribute to
the pathogenesis of IA. The degree to which each contributes to an individual’s aneurysm
is likely patient specific. We aim to identify both the genetic mutations and
environmental factors that work independently and synergistically to form IA.

ENVIRONMENT
The literature is rich with association studies linking risk factors with the
formation and rupture of aneurysms. Guidelines have been established to identify which
aneurysms should be treated and which need to be watched. Until now, these guidelines
have been largely based around aneurysm size and location.

Aneurysm Size
The notion that aneurysm size correlates with rupture risk is as old as aneurysm
surgery itself. Blood vessel walls are exposed to a combination of hydrostatic pressure
and shearing stress. It is thought that aneurysm wall stress and eventual rupture is directly
correlated with aneurysm size. Prior to the 1990s, aneurysms greater than 10 mm were
considered at high risk for rupture and treated surgically. However, contrary to the
guidelines, aneurysms < 10 mm did rupture and led to SAH in significant numbers,
prompting a reevaluation of the guidelines.
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Recent studies, including the prospective arm of the International Study of
Unruptured Intracranial Aneurysms (ISUIA), suggest aneurysms < 10 mm in size have
higher than previously predicted rates of rupture (15). These studies led to the
adjustment of clinical guidelines that treatment with either microsurgical or endovascular
techniques should be considered with aneurysms > 7mm in size (15). Despite this
recommendation a significant number of patients present with SAH due to aneurysms ≤ 7
mm in daily clinical practice. In addition, several studies have shown the decision to
treat unruptured aneurysms should not be based on aneurysm size alone (16-20).
However, the results of these studies are not yet incorporated into the treatment
guidelines.

Other Risk Factors
Many studies have attempted to identify risk factors, other than size, that predict
the formation, growth, and rupture of IA. Factors such as hypertension, atherosclerosis,
diabetes, and vascular anatomical differences have been implicated in pathogenesis (4,
21). In addition, social factors such as smoking and diet have also been suggested to play
a role in the disease (4, 22). Although family history and the above-mentioned modifiable
risk factors have been suggested to increase the risk of rupture, there is insufficient data
to support a definitive clinical recommendation for surgical treatment of small
aneurysms. (23-33)
A review by Teunissen et al. revealed only hypertension, cigarette smoking, and
alcohol consumption (greater than 150 g / week) were significant risk factors (34). These
results were confirmed in a review of five trials (North America, Canada, and Europe)
which demonstrated cigarette smoking to be a major risk factor (28).
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While there is evidence for environmental factors contributing to the pathogenesis
of IAs, they fail to explain the complete picture, especially in young adults. Thus, genetic
factors, particularly in the younger population, have been suggested to play a crucial role
in the pathogenesis of aneurysm formation.

GENETICS
It is now well accepted that genetic risk factors, in addition to environmental risk
factors, contribute to the formation and / or rupture of cerebral aneurysms. In this section,
we highlight familial intracranial aneurysms and previous linkage analysis studies.

Familial Aneurysms
The notion that aneurysms cluster in families was first noticed in identical twins
during the 1960s. Ullrich and Sugar reported 4 families, each with at least 2 members
with cerebral aneurysms (35). This was followed by several case reports of multiple
familial IA (36-41).
In 1980, Fox and Ko reported the largest family reported to date of thirteen
siblings, 6 had proven IA and 5 had normal findings on cerebral angiogram; 2 refused
angiogram (42). Subsequently, one of the two who refused workup suffered a SAH and
was found to have 2 aneurysms by angiogram. Interestingly, there was no disease in their
parents and relatives. Since then, we have ascertained and recruited this family in our
study (IA 20, figure 3) and found that there are newly affected members in subsequent
generations.
In 1993, Ronkainen et al reported a 10% incidence of familial IAs in family
members of 1,130 patients with proven aneurysmal SAH from east Finland (26).
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Similarly, Kojima et al. reported a 10% prevalence of IAs in families with positive
history (43). Two studies, a prospective and retrospective study, found a three to five
fold increase in incidence for first degree relatives in comparison to the general
population (44).
A study spanning from 1970 to 1989 evaluated the families of patients with
aneurysmal SAH reporting that 15 of 76 patients (20%) had a first- or second-degree
relative with aneurysmal SAH (45). The number of observed first-degree relatives with
aneurysmal SAH was 11, compared to an expected number of 2.66, giving a relative risk
of 4.14.
Nakagawa et al. found a significantly higher incidence of asymptomatic cerebral
aneurysms among Japanese patients with family history of SAH within the second degree
of consanguinity versus healthy volunteers (13.9% versus 6%) (46). When combined
with other risk factors such as hypertension and habitual smoking, these patients were
found to have the highest incidence.
Several studies have reported that familial IA behave differently than sporadic IA.
Familial cases are detected at an earlier age and ruptured at a smaller size when compared
to sporadic cases (47-51). In fact, 70% of familial IA rupture by the age of 50 versus 43%
of non-familial aneurysms (47). Additionally, a study by Leblanc et al. found higher than
expected concordance of the age at rupture in a prospective study of 30 individuals in 13
families with multiple affected individuals (52). In the Saguenay-Lac Saint Jean region of
the Province of Quebec, Canada, Mathieu et al. found that siblings of patients with
ruptured IA had a greater risk of ruptured IA than the general population (53).
IA transmission from generation to generation has been difficult to determine. A
review of the literature covering 238 affected families, by Schievink et al., did not find
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one pattern of inheritance nor Mendelian model that uniformly applied (44). The most
commonly affected relatives were siblings. Twenty-two percent of siblings of male
probands had an IA compared with 9% of sibs of female probands. Interestingly,
angiographic screening in 12 families detected IAs in 29% of 51 asymptomatic relatives.
Although genetic heterogeneity might be present, screening of asymptomatic relatives
could provide information as to the mode of inheritance. There is significant debate over
the mode of transmission (two-hit phenomenon, haploinsufficiency, or defective protein
(dominant negative)).

Candidate Genes
While several candidate genes have been implicated in the pathogenesis of
aneurysms, none have led to any significant findings. These genes range from those
associated with vascular wall formation to those that are mutated in connective tissue
disorders. By studying known genetic diseases with high concordance of IA, researchers
have identified proteins associated with the genetic disease as potentially related to the
pathogenesis of aneurysms. Diseases such as Adult Polycystic Kidney Disease (MIM
#173900) (54), Marfan syndrome (MIM #154700) (55), Glucocorticoid Remediable
Aldosteronism (MIM #103900) (56), and Ehlers-Danlos syndrome type IV (MIM
#130050) (57), appear to increase the risk of IA formation. This phenomenon prompted
researchers to study the gene and gene products responsible for the disease with the hopes
of explaining the increased IA formation.
Recent advances in genetic disorders and vascular abnormalities have revealed
several alterations in gene and gene products involved in the remodeling of the
extracellular matrix (ECM). The dynamic nature of the ECM has been theorized to go
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awry leading to a weakening of the vasculature ultimately resulting in an aneurysm.
Supporting this notion, the content and structure of collagen and elastin, the predominant
elements in aneurysmal walls, is significantly altered. The below mentioned ECM-related
proteins have been identified in genetic disorders and could be related to IA formation.

Elastin
In 2001, a genome-wide linkage study of 104 Japanese affected sib-pairs
identified an area near the elastin gene (ELN) as the best evidence of linkage (58).
Linkage was found at a total of three sites: 5q22-q31 (maximum lod score (MLS), 2.24),
7q11 (MLS, 3.22), and 14q22 (MLS, 2.31). None of the fourteen SNPs identified within
ELN were associated with aneurysms. However, the haplotype between intron-20 /
intron-23 polymorphism of ELN was strongly associated with intracranial aneurysms [P
= 3.81 x 10(-6)]. Further, patients who were homozygous for the mutation were at highest
risk (P = 0.002), with an odds ratio of 4.39. These findings strongly support the body of
literature implicating the ELN locus in aneurysm genesis, more specifically the locus on
chromosome 7q11.2. However, no frank mutation was identified.

Elastase / α1-Antitrypsin
Elastase is a proteolytic enzyme that degrades elastin, collagen, and other proteins
within the ECM (59-61). Secreted by polymorphonuclear leukocytes, it is inactivated
once it binds to α1-antitrypsin forming a serum complex with protease (62, 63). The
balance between active and inactive elastase has been implicated in aneurysmal
formation. Tartara et al have suggested that α1-antitrypsin activity is decreased in the
walls of intracranial aneurysms. (64) Accordingly, elevated levels of elastase are found at
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the site of intracranial aneurysms. (65) Although controversial, these complimentary
studies suggest that α1-antitrypsin levels are decreased at the site of aneurysms leading to
increases in elastase levels. However, two studies contradict these findings demonstrating
elevated elastase levels in healthy individuals without aneurysms. (66, 67) Debate over
the importance of this ratio will require further work delineating aneurysmal causes from
those of normal physiology.

Collagen (I and III)
Studies have uniformly demonstrated a decrease and alteration in the collagen
within aneurysmal walls. In particular, a deficiency in type III collagen occurs within
aneurysm walls. (68-73). Studies have proposed a defect in type III collagen (COL3A1)
(57, 72). EDS type IV is a connective tissue disorder caused by mutations in the COL3A1
gene on chromosome 2q31. EDS type IV is characterized by vascular abnormalities
consisting of increased ruptures, thin transparent skin, and ligament weakness.
Ostergaard and Oxlund demonstrated 6 of the 14 patients who died from ruptured
intracranial aneurysms had type III collagen deficiency in the middle cerebral and
brachial artery postmortem. (71) However, others have suggested that mutations in the
COL3A1 gene are not a common cause of intracranial aneurysms nor are cervical artery
dissections. (74) Although collagen constitutes the majority of the ECM, its role in
aneurysm formation, and it’s ratio to collagen III, remains unclear.

Endoglin
Endoglin, a component of the transforming growth factor-beta receptor complex
is highly expressed on endothelial cell surfaces. One study demonstrated an association
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between intracranial aneurysms and a 6-base insertion polymorphism in intron 7 of the
endoglin gene in a Japanese population. (75) This region codes for a component of the
transforming growth factor-ß receptor complex and is also mutated in Hereditary
Hemorrhagic Telengiectasia 1 (HHT1). However, two other studies, one on a Caucasian
population (63) and another on a separate Japanese population (58) failed to replicate this
result.
The discrepancy in results from the above-mentioned studies suggests that
polymorphism sequences are likely influenced by genetic and environmental factors
which differ according to ethnicity. To prove this point, ethnic related differences are
reported for polymorphisms and are considered within the norm. While the Krex and
Onda studies refute the findings of Takenaka’s study, it is possible that endoglin encodes
multiple proteins, one of which could lead to aneurysm formation. The polymorphisms
expressed in endoglin represent one of the many reasons genetic testing is complex.

Polycystin
Autosomal dominant polycystic disease (ADPKD) is characterized by renal cysts,
renal failure and vascular pathology. Disease results in a mutation in one of two genes,
PKD 1 and 2, which encode polycystin 1 and 2, respectively. Polycystin participates in
protein-protein (multiprotein membrane-spanning complex) and protein-carbohydrate
interactions in the extracellular matrix. As early as 1971, Jankowicz et al. reported an
increase in incidence of berry aneurysms in patients with ADPKD. While mutations in
both genes have been linked to intracranial aneurysms, work on PKD 1 has revealed a
specific mutation in chromosome 16p13.3 exon 15 of PKD 1 in two patients. (76).
Further, the position (not the type of PKD 1 mutation) influences a patient’s likelihood of
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developing an aneurysm. Rosetti et al. demonstrated that mutations in the 5’ half of the
gene was associated with poorer prognosis (77). The prevalence of asymptomatic
intracranial aneurysms in patients with ADPKD is five times that of the general
population (54, 78). The average age of aneurysmal rupture is 41, a decade earlier than
sporadic cases (78-80). One could speculate that the PKD 1 gene either encodes multiple
proteins or that a mutation in the 5’ end produce a dominant negative. The relationship
with PKD1 and intracranial aneurysms is rather complex and possibly due to one of the
multiple proteins encoded by the PKD1 gene.

Fibrillin
Marfan syndrome, an autosomal dominant disorder of the connective tissue,
affects the cardiovascular, skeletal and ocular system. It is characterized by
arachnodactyly, unusual height, pectus abnormalities, enlargement of the aorta and
possibly aortic aneurysms. The disease is due to a mutation in the gene encoding fibrillin
(FBN1) located on chromosome 15q21.1. There is debate over the association between
FBN1 mutation and intracranial aneurysms. A recent study of 25 autopsy cases with
Marfan syndrome revealed no statistical difference in the prevalence of intracranial
aneurysm in patients with and without Marfan syndrome.
There has been no association between FBN 1 mutations and IA, however that is
not the case for thoracic aortic aneurysms (TAA). Two influential studies have linked
chromosomes 5q13-q14 and 11q23.2-q24 with aortic and thoracic aneurysms (81, 82).
The pathogenesis of aortic and thoracic aneurysms is likely similar to that of intracranial
aneurysms and identification of the gene and gene products of one may divulge a wealth
of knowledge about the other. Currently, our laboratory is involved in a project studying
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families with both intracranial and thoracic aortic aneurysms in an effort to identify
common gene mutations.

Genome-Wide Linkage Analysis
The discrepancy in results from the above-mentioned studies reveals the
limitations of candidate gene analyses. While approaches driven by hypotheses regarding
disease mechanisms are intuitively attractive, experience has shown repeatedly that
positional cloning is the most productive method for isolating causative genes when the
pathophysiology and molecular biology of a disorder is not well elaborated. For
example, in other complex disorders such as hypertension, positional cloning approaches
by our laboratory revealed 19 genes that contribute to human blood pressure homeostasis,
some defining novel physiological pathways that would have been extremely difficult to
predict prior to our studies being completed (83). Importantly, the results of these types
of analyses serve as the basis for a wide array of hypothesis driven investigations that can
elaborate the mechanisms by which a particular gene or genes, once identified, contribute
to a disorder of interest.
To date, a number of studies have used linkage approaches to attempt to
identify loci contributing to IA risk (57, 58, 72, 74, 75, 84-86). Sib-pair studies in the
Japanese and Finnish populations and a recent report of a consanguineous Dutch family
have identified additional candidate intervals (58, 85, 87). However, only two intervals
have significant genome-wide linkage and have not been disproven; 19q13.3 in the
Finnish population (88) and 2p13 in the Dutch family (87).
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Genetics of Complex Disease
Although many diseases have genetic components, relatively few segregate in
Mendelian fashion with an identifiable single gene. A number of explanations may
account for this observation. First, the disease may be attributable to inheritance of a
single gene of incomplete penetrance, in which case only a fraction of recipients of the
mutant gene may develop the disease. Second, the disease may be caused by the
combined effects of multiple factors in individual subjects- these factors may be a
combination of genetic and environmental exposures, obscuring the effects of inheritance
of each susceptibility gene. Until recently, it seemed that the identification of genes for
these multi-factorial traits was an insurmountable barrier. However, the ongoing
revolution in genetic analysis now permits us to identify genes for complex disorders
such as IA in which there is a likely genetic component in some patients.
Importantly, the advent of imaging studies have revealed that IA is much more
common in the general population than had been previously recognized, with estimates of
the population prevalence ranging up to 10% (11). With a high prevalence such as this, it
becomes increasingly likely that, as a general rule, this trait will prove to be of multifactorial determination rather than due to inherited variation in a single gene. The upside
to this observation, however, is that it is highly likely that one will be able to identify a
sizable cohort of multiplex families relatively rapidly by ascertaining multiplex families
through affected index cases. Moreover, the availability of large pedigrees still provides
the opportunity to identify the unusual circumstance in which IA is transmitted as a
consequence of a mutation in a single with major effect. Consistent with these
observations, since 1994 we have collected nearly 142 families including both large and
small families in order to give us the power to positionally map the IA gene(s).
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Large kindreds with high incidence and prevalence of IA are likely due to a single
gene responsible for the large effect. Therefore, genome-wide linkage analysis of these
kindreds will allow one to find the chromosomal position of the disease gene by using
genetic markers. Confining analysis to a single or a few large families minimizes the
chance of obscuring linkage due to genetic heterogeneity in which the disease is caused
by mutation in different genes in different families. The disadvantage is that it is unclear
whether genes identified in such families will prove to play a role in the general
population or whether they will be of significance only in rare families. Further
complicating things, the ability to collect large extended kindreds may prove to be
exceptionally difficult due to the lethality of the trait, such that samples from known
affected subjects are unavailable. Such analysis is confounded by the uncertain genotype
of unaffected subjects.
We plan to use the large extended families we have already collected to identify a
single gene of major effect using parametric linkage analysis. Once a locus is identified,
we propose to confirm the loci by analyzing additional families.

SPECIFIC AIMS
The goal of my thesis was to identify the genetic and environmental causes of IA.
The primary project was to discover the genetic causes of intracranial aneurysms by
studying the largest-yet-reported kindred with IA. The other large IA families in our
database were used to help confirm and develop a more thorough understanding of the
molecular genetics of IA.
The second stage of the project was to define the environmental risk factors
related to IA formation. We conducted a retrospective case-control study, to identify the
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risk factors associated with the rupture of aneurysms ≤ 7 mm in size in a consecutive
series of patients. We hope to identify patient-specific risk factors that should be
considered along with IA size in determining rupture risk and treatment decisions.

MATERIAL AND METHODS
Patient Recruitment
Through collaborations with vascular neurosurgeons at a number of domestic and
international centers, we have established the Yale Brain Aneurysm Database (table 1).
Study investigators from Yale and / or physicians caring for the patient discussed
participation in the study with the index patient. Similarly, relatives were contacted and
recruited to the study either by the Yale group or the physician of the index case (after
appropriate HIC / HIPAA consent has been obtained).
Both patients with sporadic (< 2 affected members within kindred) and familial
disease (> 2 affected members within kindred) were enrolled in this database. Since 1994,
we have screened over 3000 patients with IA and identified 142 multiplex families with a
total of 345 affected patients. Twenty-one of these families have more than 4 affected
members and 4 of them have more than 7 affected members. These families are large
enough to support linkage independently. A representation of a number of the large
families is shown in Figure 1. While some families fit an autosomal pattern, analysis of
IA pedigrees show that inheritance of IA is complex. We believe these patients and
families constitute one of the largest IA databases in the world.
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Table 1: List of Collaborators and their respective institutions
Medical Center
Beth Israel Medical Center
Columbia University
Harvard - Brigham and Women's Hospital
Harvard - Brigham and Women's Hospital
Harvard – Massachusetts General Hospital
Memorial University, Newfoundland Canada
Northwestern University
Northwestern University
St. Louis University
Stanford University
Istanbul University, Turkey
Istanbul University, Turkey
University of Pittsburgh
Yale University

Collaborator
Alejandro Bernstein M.D.
Sander Connolly M.D.
Robert Friedlander M.D.
Dong Kim M.D.
Christopher Ogilvy M.D.
Falah Maroun M.D.
Hunt Batjer M.D.
Issam Awad M.D.
Saleem Abdulrauf M.D.
Gary Steinberg M.D.
Necemettin Pamir M.D.
Mehmet Kaynar M.D.
Daniel Wecht M.D.
Arun Amar M.D.

Patient Questionnaire
The first approach to identification of multiplex families was via questionnaire
administered to IA patients (see appendix). This approach was simple, rapid, and selected
for more severely affected subjects by virtue of the severity of disease presenting to
medical attention. This questionnaire includes questions regarding the patient’s current
health, past medical and surgical history, medications, allergies, and family history of IA,
stroke, and cerebral hemorrhage. In addition, participants were specifically asked about
histories of known causes of aneurysm or cerebral hemorrhage, i.e., diagnoses such as
Ehlers-Danlos, Polycystic Kidney Disease, and GRA. Data regarding the patient’s
history was obtained either directly from the patient or through participating physicians.
The questionnaire was completed either with supervision from study personnel or
by direct mailing to study participants for completion at home. Follow-up phone calls
helped ensure complete data capture. Previous protocols reveal a greater than 90%
response rate, and our protocol had similar response rates. Patients were often aware of
relatives with diagnoses or treatment for aneurysm or who have suffered a SAH.
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Relatives identified with history of aneurysm or SAH were directly contacted by study
personnel to obtain medical records to either confirm or exclude the diagnosis.
Once relatives are identified, we expanded the pedigree to include all distant
relatives in order to identify the total number of living affected members and determine
at-risk siblings and children. Individuals with unknown phenotype were imaged using
MRA or CTA. Finding a family with high prevalence of disease increased the likelihood
that a single gene accounts for most or all of the risk of aneurysm development.

Phenotype Assignment
Phenotype was ascertained through MRI/A, CTA or cerebral angiography.
Families with at least one additional affected individual (total of two affected) were
selected for study. Medical records of relatives helped determine affection status. Those
with unknown phenotype were screened by using non-invasive tests such as MRA or
CTA (which was indicated clinically). In cases where the diagnostic imaging studies
were performed at outside institutions, we obtained official radiological reports of
diagnostic studies. Relatives were classified as affected if presence of IA during these
imaging techniques. Unaffected relatives <30 years old were classified as phenotype
unknown. All phenotypes were assigned prospectively by Dr. Gunel.
Screening of family members with more than 2 affected is indicated clinically
(89-93) and has been funded by insurance companies. Despite the consensus within the
neurosurgical community regarding scanning of these at-risk individuals, funding of the
imaging tests is often a potential problem with the insurance companies. In a number of
occasions when we encountered this problem, one-to-one discussion with the insurance
companies was necessary in order to gain approval to scan the at-risk individuals.
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Figure 1:
Representation of several of the large kindreds with intracranial aneurysms in the Yale Brain Aneurysm
Database. Affected and unaffected individuals are shown as blackened and nonblackened symbols,
respectively. Obligate carriers are shown as partially blackened symbols.
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Record Review
In order to identify eligible patients with SAH, we initially conducted a
retrospective chart review on 336 patients presenting with any type of intracranial bleed
from January 2001 to 2004 to the Yale Brain Aneurysm and AVM Center. Of the 336
charts reviewed, 100 eligible patients with SAH due to IA ≤ 7mm were identified.
Subjects with SAH due to aneurysms > 7mm (n = 52) were excluded from the study, as
were SAH without documented IA on angiogram (n = 26), intracerebral hemorrhage (n =
97), subdural hemorrhage (n = 40), or bleeding due to trauma (n = 21). This was the only
SAH for any of the patients in the ruptured group. Furthermore, no pre-hemorrhage data
was available for many of the ruptured patients and this was excluded from the data
series. Control subjects were referred due to a variety of reasons ranging from trauma,
family history, or workup for headaches. Patients with unruptured aneurysms, but a prior
history of subarachnoid hemorrhage were excluded from the control group.
Aneurysm size was obtained from conventional angiography or 3D computerized
angiography (CTA). Clinical data, past medical history, and other data were obtained
from clinic, hospital charts, and radiological reports. We contacted patients directly in
the event of incomplete medical record data. In two cases of deceased patients, we
obtained information from the patient’s next of kin and confirmed these results with the
patient’s primary care physician. All aneurysms were berry aneurysms of the circle of
Willis vessels. Dissecting aneurysms were excluded from the analysis.

Clinical Definitions
Patients were coded with hypertension or hypercholesterolemia if either diagnosis
was present in the clinical chart prior to admission or clinic visit. Hypertension and/or
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hypercholesterolemia were identified by the patients’ primary care physicians prior to
hospital admission or presentation to clinic. Information regarding smoking, alcohol and
cocaine use, and family history (intracranial aneurysms hypertension, and abdominal
aortic aneurysms) was obtained from charts. Age at presentation was defined as the
patient’s age upon admission, clinic visit, or diagnosis of unruptured aneurysm.
Aneurysm location was classified as anterior circulation (anterior cerebral,
anterior communicating, internal carotid, middle cerebral, ophthalmic, para-ophthalmic,
and posterior communicating artery) or posterior circulation (basilar, posterior inferior
cerebellar, and posterior / superior cerebellar artery) according to anatomical convention.

Statistical Methods
Using the Fisher exact test for categorical variables and Spearman’s correlation
coefficient for ordinal variables, we performed univariate comparisons between putative
predictor variables and the outcome of aneurysmal rupture. Age was analyzed as an
ordinal and dichotomous variable comparing patients younger than 50 years of age to
those older than 50. A two-tailed p value < 0.05 was chosen as the threshold for
statistical significance. All variables with a p value of 0.2 or lower were entered into a
multivariable logistic regression model. Adjusted odds ratios were reported based on the
results of logistic regression analysis. Model fit was assessed by standard methods,
including residual diagnostics and Hosmer-Lemeshow goodness-of-fit testing. Model
performance was assessed by the Nagelkerke R2 estimate and computed prediction errors.
All statistical analyses were done using SPSS 12.0 (SPSS, Inc, Chicago, IL).
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Meta-Analysis
Under the guidance and expertise of Dr. Tom Morgan, we sought to aggregate all
previously published data to improve the precision of our estimates in defining the impact
of risk factors leading to rupture of IA ≤ 7 mm. To accomplish this, we used methods
previously described for meta-analysis of case-control data (94) We performed a
comprehensive literature review by searching PubMed and Medline using various
combinations of the following keywords: "subarachnoid hemorrhage", "intracranial
aneurysms", "unruptured", "ruptured", and "risk factors". In addition, we manually
searched the bibliographies of existing reports to identify citations not included in
Medline. Using previously established guidelines we systematically reviewed these
articles (95) Our inclusion criteria were: prospective or retrospective study; must contain
comparison of ruptured vs. unruptured ICA; risk factor data must be reported by
subcategory of aneurysm size (up to 10 mm accepted as cut-off for subgroup analysis);
and populations must be comparable in terms of age and co-morbidity.

Preparation of Human Genomic DNA
A 20 ml sample of venous blood was collected in acid citrate-dextrose tubes from
each adult subject and shipped to Yale at room temperature via overnight courier. For
pediatric subjects, no more than 10 ml/30 kg of body weight was collected. DNA was
prepared by isolation of nuclei followed by proteinase K - SDS lysis and subsequent
phenol and chloroform extractions, after which the DNA was precipitated with ethanol
and resuspended in 10 mM Tris, pH 8.0, 0.1 mM EDTA. For samples that had been
previously frozen, the yield of intact nuclei was very low, and we consequently modified
the method to perform direct lysis of whole blood using high concentrations of proteinase
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K, following which the protocol followed as above. This approach was inexpensive and
had a long standing history of producing good yields. We have used this protocol for
over 10 years and have had no problems with PCR amplification, restriction
endonuclease digestion, cloning, or long-term stability of samples.
DNA isolation was performed in a dedicated room to prevent potential
contamination of the laboratory environment with genomic DNA. Yield averages
approximately 1 mg DNA, and was less than 200 ug in only 2% of samples. Because we
use 50 ng DNA per PCR reaction, we could genotype 400 markers with only 20 ug DNA,
leaving large quantities of each sample for subsequent analysis as needed. The optical
density at A260 and A280 is read to determine the concentration of each sample, and is
>1.8 in 98% of samples prepared from fresh blood and 85% of samples prepared from
frozen specimens. Primary isolates were stored in eppendorf tubes at –70oC. Access to
these samples was restricted to the DNA database manager. When samples were used, a
master stock of samples were aliquoted at a concentration of 100 ug/ml in 96-well plates
and working stock dilutions were prepared from this master stock, and these stocks were
maintained by individual investigators.

SNP Genotyping
GeneChip genotyping was performed by and in collaboration with the Keck
Affymetrix GeneChip Center under the expertise of Shrikant Mane Ph.D. We used a twostage design in linkage analysis (96). We first genotyped all available affected
individuals (n=6) using an early access version of the Affymetrix 10K GeneChips
containing 10,044 SNP markers (Affymetrix: Santa Clara, CA) . The median intermarker
distance with this approach was 105 kb, and the mean heterozygosity of markers was
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0.39. The SNPs genotyped on these chips provide an estimated information content
equivalent to a microsatellite screen density of one marker per 1 - 2.5 cM (97). SNP
genotypes are obtained by following the Affymetrix protocol for the GeneChip Mapping
10K Xba Array. Briefly, 250 ng of genomic DNA was digested per sample with the
restriction endonuclease XbaI for 2.5 h. Digested DNA was mixed with Xba adapters and
ligated using T4 DNA ligase for 2.5 h. Ligated DNA was added to four separate PCRs,
cycled, pooled, and purified to remove unincorporated ddNTPs. The purified PCR
products are then fragmented and labeled with biotin-ddATP. Biotin-labeled DNA
fragments are hybridized to the mapping 10K array 130 chips for 18 h in a standard
Affymetrix 640 hybridization oven. After hybridization, arrays were washed, stained, and
scanned using an Affymetrix Fluidics Station F400 with images obtained by use of the
Affymetrix GeneArray scanner 2500. Affymetrix MicroArray Suite 5.0 software was
used to obtain raw microarray feature intensities (raw allele scores (98)). Using
Affymetrix Genotyping Tools software package we derived the SNP genotypes.

Genechip Data Analysis
Using the Genome Analysis Programs provided by Affymetrix, we analyzed
Genechip data. We created a UNIX based program (Chunky) that parses the data sheet
into individual files per chromosome in linkage format by generating a data sheet with
the following information: chromosome number, SNP markers, Decode Map Distances,
Genotype Calls, and Allele Frequencies (provided by NetAffymetrix).
We used multipoint linkage analysis assuming autosomal dominant inheritance
and assign either a 70, 90, or 99% penetrance. Analysis will be done using the Allegro
program (DeCode Genetics, Iceland). Allele frequencies for the GeneChips SNPs will be
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obtained from Affymetrix (http://www.laboratorytalk.com/news/aff/aff101.html).
However, since a number of our pedigrees had a mixture of different ethnic groups, the
allele frequencies provided by Affymetrix which was based on 54 individuals, may not
have been suitable for the study population. Therefore, we also examined the robustness
of linkage analysis using alternative approaches to specifying allele frequencies.
The 10K Genechips provided enough power to identify broad structures in the
sample using statistical methods (e.g. the STRUCTURE program developed by Dr.
Pritchard and colleagues). In this analysis, unrelated individuals from each family were
used to infer population structure. This allowed us to group families into more
homogeneous groups. Then based on the inferred groups, we considered three
approaches for allele frequency specification. First, for groups with a large number of
families, we collected data to infer allele frequencies based on unrelated individuals in
these families. Second, as these large groups likely corresponded to populations with
known allele frequencies, e.g. European Americans, and allele frequencies from such
populations may be available in the public domain (e.g. Affymetrix and the international
HapMap project), we used population data to investigate the robustness of linkage
analysis results. These different approaches ensured that our report of linkage had
enough confidence that they were not due to allele frequency misspecifications. The map
order and distances between SNP markers are based on the latest build of the UCSC
Genome Browser (May 2004, genome.ucsc.edu).
We confirmed the results of the Allegro program by using GENEHUNTER.
Since GENEHUNTER can only handle 50 markers at most, we created a Unix based perl
script that finds 50 markers within the maximum lod score interval. This program also
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generates pedigree and data file to be fed into the GENEHUNTER program. Previous
runs have shown consistent results between Allegro and GENEHUNTER programs.
Establishment of proper threshold for statistical significance is crucial for linkage
association studies. In general, LOD scores of 3.3 are accepted as significant for
parametric linkage studies, while for non-parametric tests threshold values p = 2-5×10-5
or LOD >3.7 are necessary to declare significance (99, 100). Loci were also examined
under models of locus heterogeneity, using 3.3 as threshold for significance (101). For
Mendelian traits segregating in many independent families, if linkage under models of
locus homogeneity were not apparent after exhausting potentially linked intervals, we
then performed analysis allowing for locus heterogeneity (101). If a locus was identified,
multilocus analysis was performed to search for additional loci that explained disease in
remaining kindreds (102, 103). We used the suggested threshold point-wise p-value of
0.01 which corresponded approximately to a LOD score of 1.5 (99). These guidelines are
generally accepted for genome-wide significance levels for linkage studies. (99, 100).

Confirmation of Linkage Using Microsatellite Short Tandem Repeat (STR) Markers:
The above-mentioned approach provides suggestive genomic regions with lod
scores close to the theoretical maximum lod score. Microsatellite short tandem repeat
(STR) markers were identified within these regions using the physical map data from the
UCSC Genome Browser (May 2004, genome.ucsc.edu). These were genotyped for
further mapping using all available members of a particular family, affected and
unaffected. This strategy has been often referred as a two-stage design in linkage
analysis (104). The theoretical properties of this strategy have been explored by
researchers and some software provided guidance on the application of this strategy (e.g.
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DESPAIR in SAGE). We followed these established principles in the selection of
promising regions to follow up using microsatellite markers. All genotyping for
microsatellite analysis were performed by polymerase chain reaction, with detection of
fluorescent products on an ABI 3700 sequencer from Applied Biosystems equipped with
Genescan and Genotyper software (ABI, Norwalk, CT).
PCR reactions were performed in 96-well plates using MJ Research DNA Engine
Tetrad thermal cyclers, using 50 ng DNA as template in a 10 uL reaction (MJ Research:
Waltham, MA). The reaction mixture contains 1 uL 10X buffer, 1.25 nmole of each
dNTP, 50 pmole of each primer. PCR conditions involve denaturing for 30 sec at 95oC,
annealing at specified temperature for 30 sec, elongation for 45 sec at 72oC, for 35 cycles.

Electrophoresis
Genotyping and electrophoresis were performed in collaboration with the Keck
Laboratory at Yale. Keck DNA Sequencing Resource provided high volume DNA 96- or
384-well plate genotyping under its DNA Sequencing Resource. During 2002, the DNA
Sequencing Resource completed 164,910 services for 286 Yale and 102 non-Yale
investigators at 52 different institutions. Detailed information regarding this service is
available at: http://info.med.yale.edu/wmkeck/dnaseq. Sequence turnaround time is
typically two to three days for all services offered.
Advantages of the ABI 3700 include automated sample loading, shortened run
times, and elimination of gel pouring and lane tracking. One uL of pooled sample were
mixed with 2.0 uL formamide, 1 uL ROX labeled size standard and 1 uL of loading
buffer and denatured for 3 minutes. In brief, 96–well plates containing these denatured
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PCR mixtures were loaded on the sequencer which automatically transfers and injects
individual samples into 96 glass capillaries filled with a stationary polymer.
After electrophoresis through the capillary tubes, the samples were ejected into a
transparent cuvette, which were scanned by a laser beam that detects fluorescence. The
ABI 3700 capillary sequencer cannot distinguish between TET and 6-FAM labeled PCR
products. To avert this problem, a novel dye, NED, has been developed by Perkin-Elmer
to replace TET in ABI 3700 runs. We converted the TET labeled primers (N=139) used
for the ABI 377 to the NED label. In addition, ROX-labeled size standards were used
instead of TAMRA labels. Genotypes are obtained with the ABI 3700 (Perkin Elmer,
CA) DNA sequencers using the compatible Genescan and Genotyper software programs.
Once the data was read, it was processed and stored as a sample file in the
instrument database and displayed as an electropherogram. The sample files were
imported into the Genescan analysis software (Version 3.5 NT) and run on a PC
compatible computer with the Windows NT operating system. Sample sizes were
calibrated using the Genescan 500 ROX standard. After analysis with the size standard,
the samples files were imported into the Genotyper software (Version 3.5) for
determination of genotypes. Allele sizes were determined by an investigator blinded to
patient characteristics. The allele size data were exported into a data sheet and converted
to allele numbers and associated with patient identification numbers and phenotypic
status for analysis of linkage.

Data Management and Storage
All GeneChip data was stored in Sun Sparc workstations and all microsatellite
STR genotyping data was stored in the Cyrillic program. These files were backed up on
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CD-ROM and UNIX-based linkage input and output were backed up on high capacity
tape drives. ABI files containing sequence runs which were typically 25-28 MB in size
were achieved by backup to CD-ROM discs that were stored in the laboratory.

RESULTS
Hypertension
SAH secondary to IA ≤ 7 mm occurred in 76.5% of patients with pre-existing
hypertension, whereas only 55.9% of people with normal blood pressure experienced IA
rupture. In the univariate analysis, hypertension was a significant risk factor for IA ≤ 7
mm rupture with odds for rupture of 2.58 (p value = 0.01).

Aneurysm Location
Although the majority of aneurysms were in the anterior circulation, rupture rates
differed greatly according to aneurysm location. Within the unruptured group, carotid
(n=15), MCA (n = 13) and ACoA (n = 8) IAs were the most common. Among the SAH
group, ACoA (n = 26), PCoA (n = 26), and MCA (n = 19) were the most common
locations of IAs. Eighteen of the 21 (85.7%) aneurysms located in the posterior
circulation ruptured, whereas 82 of the 130 (63.1%) anterior circulation IAs ruptured.
Posterior circulation conferred increased risk for IA rupture, OR = 3.51 (p < 0.05).

Age of Presentation
The median age of patients in our sample was 52. We chose to dichotomize at 50
years old as this is a clinically useful cutoff point where surgical morbidity and mortality
increases (morbidity 5.6% at 1 year for patients < 50 years old). (15) There was no
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significant correlation between age and rupture in the univariate analysis (Spearman’s rho
= -0.11; p = 0.17). However, the adjusted multivariate analysis showed a risk increase of
2.6% (p = 0.07) with each one-year decrease in age.

Table 2: Clinical variables and risk of cerebral aneurysmal rupture

Variable

Value

Proportion
with IA
rupture (%)

Unadjusted OR Fisher exact
(95% CI)
p value

Age

< 50 years 49/69 (71.0)
≥ 50 years 51/82 (62.2)

1.49 (0.71, 3.13)

0.30

Sex

Female
Male

81/123 (65.9)
19/28 (67.9)

0.91 (0.35, 2.37)

1.00

IA size

5-7 mm
1-4 mm

50/73 (68.5)
50/78 (64.1)

1.22 (0.59, 2.53)

0.61

IA number

2+
1

23/37 (62.2)
77/114 (67.5)

0.79 (0.34, 1.83)

0.55

IA location

Posterior
Anterior

18/21 (85.7)
82/130 (63.1)

3.51 (0.95, 19.4)

0.05

Hypertension*

Yes
No

62/81 (76.5)
38/68 (55.9)

2.58 (1.21, 5.53)

0.01

Hypercholesterolemia* Yes
No

27/40 (67.5)
56/76 (73.7)

0.74 (0.30, 1.86)

0.52

Smoking*

Yes
No

59/83 (71.1)
35/53 (66.0)

1.26 (0.56, 2.83)

0.57

Cocaine use*

Yes
No

5/7 (71.4)
44/63 (69.8)

1.08 (0.16,12.3)

1.00

Family history IA*

No
Yes

77/111 (69.4)
18/30 (60.0)

1.51 (0.60, 3.75)

0.38

Family history HTN*

Yes
No

23/31 (74.2)
72/110 (65.5)

1.52 (0.58, 4.10)

0.40

Family history AAA*

Yes
No

3/3 (100)
92/138 (66.7)

Undefined

0.55

* Differences in denominators reflect incomplete or missing data in some chart reviews.
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Aneurysm Size
Of the 336 patients with intracranial hemorrhage in this study, 152 had SAH due
to an aneurysm; 100 (65.7 %) of these were found to have an aneurysm < 7 mm in size.
As shown in Table 2, aneurysm size ranged from 1 to 7 mm. The median size in the
rupture group was 5 mm; 74 patients had aneurysms of 5 mm and greater, while 78
patients had aneurysms between 1 and 5 mm. Size was not an independent risk factor for
IA rupture under 7 mm (unadjusted OR = 1.22; p value = 0.61). The correlation between
aneurysm size and rupture was not statistically significant (Spearman’s rho = 0.10; p =
0.22). Figure 2 presents the respective distributions of ruptured and unruptured
aneurysms by size in millimeters, showing no impact of size on risk of rupture.
ICA + SAH
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Figure 2:
Frequency of subarachnoid hemorrhage (SAH) in patients with intracranial aneurysms (IA) by IA size.

31
Sex, Hypercholesterolemia, Smoking, and Cocaine Use
Similar to previous studies, more females (n = 123) than males (n = 28) presented
with IA. However, there was no statistically significant relationship between sex and risk
of rupture (p = 1.00). Additionally, neither hypercholesterolemia (p = 0.52) nor smoking
(p = 0.57) were associated with rupture. Cocaine use was also not statistically significant
(p = 1.00), although lack of data in many charts limits the interpretation of this finding.

Logistic Regression Analysis
There was a statistically significant association between hypertension and the risk
of IA rupture (p = 0.01). In addition, there was an increased risk of IA rupture with
posterior location (p = 0.048). There was an insignificant inverse correlation between
age and risk of rupture (Spearman’s rho = -0.11; p = 0.17). No other variable was
associated with IA rupture at the p ≤ 0.2 level. Thus, we entered age, hypertension, and
aneurysm location into a logistic regression model. Inclusion of these three variables
explained 14% of the variance in outcome (Nagelkerke R2 = 0.14). The multivariable
model performed better for predicting rupture (89% correct) than non-rupture (24.5%
correct). Overall, the model's predictive accuracy was 67.8%.
Hypertension was an independent risk factor for IA rupture, with an adjusted odds
ratio (95% CI) of 3.05 (1.33, 6.25), and p value = 0.004. Likewise, posterior aneurysmal
location conferred increased risk for IA rupture, OR = 5.35 (1.15, 25.0), p = 0.03. With
each one-year decrease in age, the risk of IA rupture in this sample increased by 2.6%
(OR = 1.03, 95% CI 1.00, 1.07; p value 0.07).

Meta- Analysis and Literature Review
A thorough review of literature identified 25 studies that reported risk factors for
SAH. However, none met our inclusion criteria nor were suitable to add or compare to
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our own data (Table 3). The identified studies were excluded due to violation of one of
two criteria; (1) study did not contain comparison of rupture vs. non-rupture of IA; or (2)
study did not report risk factor data by subcategory of aneurysm size (up to 10 mm
accepted as cut-off for subgroup analysis) in both cases and controls.
Table 3: Literature review results of 25 studies comparing SAH and risk factors
Author

Citation

Type of Study

Exclusion criteria*

De La Monte et al.
Asari et al.
Juvela et al.

Am J Med 78, 957-64 (1985)
Clin Neurol Neurosurg 95, 205-14 (1993)

2
2

Stroke 24, 639-46 (1993)

Retrospective (autopsy)
Prospective
Prospective

Ujiee et al.

Stroke 24, 1850-6 (1993)

Retrospective

2

Rosenorn et al.

Br J Neurosurg 8, 73-8 (1994)

Prospective

1

Mizoi et al.

Surg Neurol 44, 114-20

Prospective

2

Taylor et al.

J Neurosurg 83, 812-9 (1995)

Prospective

2

Qureshi et al.

Neurosugery 43, 22-6

Retrospective

1

Menghini et al.

Neurology 51, 405-11

Prospective / Retrospective

2

Juvela et al.

J Neurosurg 92, 390-400 (2000)

Prospective

1

Juvela et al.

Stroke 31, 392-7 (2000)

Prospective

1

Juvela et al.

J Neurosurg 93, 379-87 (2000)

Prospective

2

Nanda et al.

Neurosurgery 46, 1063-7

Retrospective

1

Qureshi et al.

Neurosurgery 46, 44-50 (2000)

Prospective

1

Roos et al.

Neurology 54, 2334-6 (2000)

Prospective

1

Ellamushi et al.

J Neurosurg 94, 728-32 (2001)

Retrospective

1

Forget et al.

Neurosurgery 49, 1322-5

Retrospective

1

Isaksen et al.

J Neurol Neurosurg Psych 73, 185-7 (2002)

Retrospective

1

Weir et al.

J Neurosurg 96, 64-70 (2002)

Retrospective

2

Winn et al.

J Neurosurg 96, 43-9 (2002)

Retrospective

1

Juvela et al.

Stroke 34, 1852-7 (2003)

Prospective

2

Matsumoto et al.

Surg Neurol 60, 516-22

Prospective

1

Ogilvy et al.

Neurosurgery 52, 82-7

Prospective

1

Wiebers et al.

Lancet 362, 103-10 (2003)

Prospective / Retrospective

2

Ohashi et al.

Surg Neurol 61, 239-45 (2004)

Retrospective

1

Exclusion criteria: (1) Study did not compare rupture vs. no rupture of IA
(2) Study did not report risk factor data as a subcategory of aneurysm size.
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Figure 3:
IA 20 kindred. Affected and unaffected individuals are shown as filled and unfilled symbols, respectively.
Individuals I-2, II-5, and IV-1 were assigned affection status unknown prior to linkage analysis and as such
are depicted with grey symbols. The genotypes of STR marker loci spanning 14 cM at 1p35-36 are shown
and segments of the haplotype linked to the disease phenotype are enclosed in a box.

IA 20 Phenotype
We focused our efforts on the IA 20 family (fig. 3), because it has the largest
number of affecteds within our database and is also has the largest number of affecteds
within a family reported in the literature (42). When first described, the IA family had
six members with proven IA, all in generation II. The pedigree has since been extended
and further characterized. In total, there are now 10 documented IAs, one subject with
distinctive multiple intracranial vessel occlusions and extensive collateral vessel
formation of unknown etiology (subject III-3), and one subject with abdominal aortic
aneurysm (AAA) at a young age (age 32; individual II-5); this latter trait is sometimes
associated with IA (105). For the purpose of linkage analysis, the documented IAs and
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the patient with multiple intracranial vascular occlusions were classified as affected and
the one with AAA was prospectively classified as phenotype unknown.
There are also 12 unaffected descendents of subject I-2. Of these, eight were
asymptomatic over age 30 and had negative screening MRI or angiography (individuals
II-3, II-6, II-11, II-14, III-1, III-2, III-8, IV-2); three offspring of unaffected subjects were
asymptomatic over age 30 and did not have screening studies (individuals III-4, III-9, III10); one was asymptomatic under age 30 without screening studies (individual IV-1).
For linkage studies, this latter subject was classified as phenotype unknown, and the
others were classified as unaffected.
Table 4: Clinical data of IA 20
AFFECTED

UNAFFECTED

ID

Aneurysm Location *

Age of
Onset

II-2

ACoA

38

II-3

Normal Angiogram

II-7

ACA, Lt MCA

53

II-6

Normal Angiogram

40

II-11

Normal Angiogram
Normal Angiogram

II-9

ACoA

ID

Study

II-15

Lt MCA

29

II-14

II-16

Lt MCA (SAH)

32

III-1

Normal Angiogram, MRA

II-17

OphtA (SAH)

57

III-2

Normal MRI, MRA

II-18

Rt MCA, ACoA (SAH)

32

III-4

No study

29

III-8

Normal Angiogram
No study

II-19

Lt ICA (SAH)

III-3

Bilateral MCA occlusion

30

III-9

III-7

Lt MCA

36

III-10

No study

IV-3

Basilar, Rt MCA X 2

21

IV-2

Normal MRI

* SAH: subarachnoid hemorrhage;
ACA: anterior cerebral, ACoA: anterior
communicating, ICA: internal carotid,
MCA: middle cerebral, OphtA: ophthalmic arteries.

UNKNOWN
ID

Study

II-5

Normal Cerebral Angiogram-AAA

IV-1

No study

Clinical features of affected members are presented in Table 4. Age of diagnosis
of IA ranged from 21 to 53 years by MRA or angiography prior to SAH (n = 7), and from
ages 29 to 57 for patients presenting with SAH (n = 4). There are scant risk factors for
IA among kindred members; specifically, there is a history of hypertension in only one
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individual and while smoking was prevalent among both affected and unaffected family
members, there was no significant difference between the two groups (8 of 10 affected
and 10 of 12 unaffected). Specifically, there is no history of polycystic kidney disease
(no history of end stage renal disease, and no serum creatnine level > 1.5 mg/dl); no
history of Marfan syndrome (no history of aortic dissection, ectopia lentis, etc.); no
history of Ehlers Danlos (no history of hypermobile joints, hyperextensible skin, or easy
scarring). Finally, in neither the affected only nor the affected plus unaffected genomewide linkage analysis (see below) was there evidence of linkage to known loci for any of
these syndromes. Members of both genders are affected, the trait is present in consecutive
generations, all affected members are the offspring of either known or suspected IA
cases, and approximately half the offspring of such subjects have IA (fig. 2). These
findings are consistent with autosomal dominant transmission of IA with high penetrance.

Linkage Analysis
An average of 9468 genotypes was scored per subject (SNP call rate range: 91% –
97%). To analyze the Genechip data for linkage we created a UNIX based program
(Chunky) that parses the data sheet into individual files per chromosome in linkage
format. Information captured includes chromosome number, SNP markers, map
distances, genotype calls, and allele frequencies.
We used multipoint analysis of linkage, we specified the disease locus as
autosomal dominant, with penetrance that varied from 70% to 99%, a mutant diseasegene frequency of 0.001, and a phenocopy rate of 0.001. SNP allele-frequency data for
the white population, as supplied by Affymetrix, were used for the analysis of linkage,
which was performed using the Allegro program (de-CODE). This analysis identified
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Figure 4:
Analysis of linkage in IA 20 from GeneChip data of affected individuals only. Linkage graphs for all
chromosomes are shown: x-axis corresponds to genetic distance (cM) and y-axis shows lod score.
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Figure 4 continued:
Analysis of linkage in IA 20 from GeneChip data of affected individuals only. Linkage graphs for all
chromosomes are shown: x-axis corresponds to genetic distance (cM) and y-axis shows lod score.
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three intervals with LOD scores near the theoretical maximum of 1.8 (1p34.3-p36.13,
1q31-q41, and 2p11-p14), with LOD scores of approximately 0 for nearly all of the
remainder of the genome (fig. 4).
The LOD scores were confirmed using the GENEHUNTER program. In an
additional analysis, we specified the trait locus as X-linked dominant, with otherwise
similar estimates of the trait locus; no interval on the X chromosome achieved a LOD
score 1_0.2. Additional genotyping with GeneChip of four unaffected individuals yielded
only these same three intervals with LOD scores of 1.0. Changing the phenocopy rate had
small effects on the LOD scores and did not identify additional candidate intervals.

Table 5: Maximum lod scores for linkage of STRs and IA with varying penetrances
Interval
1p35 – 1p36
1q31 – 1q41
2p11 – 2p14

70%
3.4
1.3
-0.3

Penetrance
90%
3.9
-0.1
-2.3

99%
4.2
-5.6
-6.6

Maximum lod scores are reported for 1p35 – 1p36, 1q31 – 1q41, and 2p11 – 2p14 using STR markers in all family
members with varying estimates of penetrance.

Using data from the University of California–Santa Cruz (UCSC) Genome
Browser (May 2004) (UCSC Genome Bioinformatics Web site), we identified and
genotyped from five to nine highly polymorphic di- and tetranucleotide microsatellite
markers across each of the three candidate intervals in all available kindred members.
Genotyping for microsatellite analysis was per- n p 23 formed by PCR, with detection of
fluorescent products on an ABI 3700 sequencer (Applied Biosystems) equipped with
GeneScan and Genotyper software (Applied Biosystems). The results were analyzed
using the Simwalk program (we specified marker heterozygosities of 75% and the same
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autosomal dominant model of the trait locus used above, with penetrance of 70%–99%).
Our analysis diminished the evidence of linkage to 1q31-q41 and 2p11-p14 (table 5). In
contrast, it demonstrated that all affected members inherit the same haplotype at 1p34.3p36.13; this haplotype was transmitted to none of the unaffected members (fig. 3).
Parametric linkage analysis (with 99% penetrance specified) yielded a maximum
LOD score of 4.2 at 1p34.3-p36.13 (table 5 and fig. 5); changing estimates of marker
allele frequencies had negligible effects on the LOD score. The likelihood of linkage to
1p34.3-p36.13 was nearly 1,000-fold more likely than the next-most-likely interval at
1q31-q41 (table 5). The LOD score peak occurs at UT646; the LOD-1 interval is flanked
by loci D1S199 and D1S496 (fig. 5), which define a 12.5-cM interval that corresponds to
a 15-Mb segment (from 19.3 million bp to 34.9 million bp). This is the same interval
defined by the GeneChip analysis, which indicated a LOD-1 interval flanked by
rs950922 and rs514262 that corresponded to a 15.4 million–bp interval (from 21.3
million bp to 36.7 million bp on 1p34.3-p36.13).
Analysis of critical recombinants supports localization of the IA locus within the
specified interval. Affected subject II-9 is recombinant at the distal border, and subject
III-7 is recombinant at the proximal border (fig. 3). Nearly identical borders define the
linked interval by SNP analysis. Examination of the LOD-1 interval identified 240 genes.
Among these, a number of genes have been identified as plausible candidate genes,
including polycystic kidney disease–like 1, brain-specific angiogenesis inhibitor 2,
fibronectin type III domain–containing gene, and collagen type XVI a1.
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Figure 5:
Analysis of linkage with microsatelite markers on 1p35-36 localizes the gene causing IA to a 12.5 cM
region between markers D1S199 and UT5144 with a maximum lod score of 4.2. Multipoint analysis of
linkage comparing segregation of IA and marker loci was performed. The location of maker loci used is
indicated at the top of the diagram. The horizontal bar indicates the extent of the lod-1 interval.

DISCUSSION
The pathogenesis of intracranial aneurysms has been associated with genetic and
environmental factors; however, a definitive mechanism has yet to be worked out. In this
thesis, we took a comprehensive approach to studying the pathogenesis of intracranial
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aneurysms. Through efforts both domestic and internationally, we have amassed one of
the largest databases of IA patients – a resource which has enabled us to study the
environmental and genetic factors associated with formation, growth and rupture of IA.
Previous genome-wide linkage studies have used affected sibling and / or relative
pairs to identify various loci throughout the human genome that link to IA (58, 84, 85,
88). However, the results of these studies have been inconsistent, inconclusive, and have
not identified a gene leading to IA. Candidate gene studies have been equally
unsuccessful (58, 84, 88, 106).
Given the substantial locus heterogeneity, the power of affected sibling pair
studies or affected relative pair studies is severely limited (107). Alternatively, using rare
Mendelian forms of IA, we focused on individual families to identify genes and pathways
that play a key role in the pathogenesis of both the rare and common form of IA (108).

Genetics
In the present study, we have investigated what we believe is the largest-yetreported kindred with IA; genome-wide analysis of linkage provides significant evidence
that the disease in this family is attributable to inheritance of a single locus at 1p34.3p36.13. Our analysis diminished evidence for linkage to 1q32.1 and 2p12 (table 5). In
contrast, it demonstrated that all affected members inherit the same haplotype at 1p34-36,
while this haplotype was transmitted to none of the unaffected members (fig.3).
Parametric linkage analysis specifying 99% penetrance yielded a maximum lod score of
4.2 at 1p34-36 (table 5 and fig. 3); changing estimates of marker allele frequencies had
negligible effects on the lod score. The likelihood of linkage to 1p34-36 was nearly 1000
fold more likely than the next most likely interval at 1q32.1 (table 5).
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The lod score peak occurs at UT646; the lod-1 interval is flanked by loci D1S199
and D1S496 (fig. 3), defining a 12.5 cM interval which corresponds to a 15 Mb segment
extending from 19.3 to 34.9 million base pairs. This is the same interval defined by
GeneChip analysis which indicated a lod-1 interval flanked by rs950922 and rs514262,
corresponding to a 15.4 million base pair interval (from 21.3 to 36.7 million base pairs on
1p34-36).
Analysis of critical recombinants supports localization of the IA locus within the
specified interval. Affected subject II-9 is recombinant at the distal border, and subject
III-7 is recombinant at the proximal border (fig. 3). Nearly identical borders define the
linked interval by SNP analysis.
Examination of the lod-1 interval identified approximately 240 genes. Among these, a
number of genes have been identified as plausible candidate genes including Polycystic
Kidney Disease Like-1 gene, Brain Specific Angiogenesis Inhibitor 2, Fibronectin type
III domain containing gene, and Collagen type XVI α1 gene.
To our knowledge, the present kindred is the largest yet reported with IA, with
10 definitively affected subjects and one likely affected subject. Genome-wide analysis
of linkage in this kindred demonstrates complete linkage of IA to a 12.5 cM segment of
chromosome 1, with evidence for linkage that substantially exceeds thresholds for
significance. The phenotyping in the kindred was clear-cut; reclassifying the patient with
multi-vessel occlusions and extensive collateral growth as phenotype unknown would
reduce the maximum lod score to 3.9. Moreover, the lod score was substantially
increased by inclusion of unaffected family members, supporting high penetrance of the
trait locus. It is also of note that the subject with the early AAA inherited a segment of
the linked haplotype, suggesting that this vascular aneurysm might be attributable to
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inheritance at this same locus. It would be of interest to obtain abdominal ultrasounds in
kindred members in order to determine whether this phenotype commonly co-segregates
with intracranial aneurysms and/or linked haplotypes. The pattern of segregation and the
linkage data indicate that this family defines a new Mendelian form of IA that is
transmitted as an autosomal dominant trait with high penetrance. Similar to reported
cases of familial IAs, members of IA 20 presented with SAH or symptomatic findings at
an earlier age than typically found in sporadic cases (47).
These findings represent a first step in identifying a susceptibility gene for
intracranial aneurysm. Other than young age, there are no obvious clinical features that
would separate IA in members of this family from typical cases in the general population.
It is presently unknown whether the locus implicated in this study might play a role in
other common forms of IA. In principle, it is possible that this might be a one-of-a-kind
family with a rare mutation resulting in a highly penetrant form of IA. It is also possible
that other less penetrant mutations in the same gene or pathway play a role in more
common forms of IA. To date, a number of studies have used linkage approaches to
attempt to identify loci contributing to IA risk (57, 58, 72, 74, 75, 84-86). Sib pair
studies from Japanese and Finnish populations and a recent report of a consanguineous
Dutch family have identified candidate intervals (58, 85, 87). The only intervals from
such studies that meet genome-wide evidence of significant linkage is 19q13.3 in the
Finnish population (88) and 2p13 in the Dutch family (87).
The identification of the causative gene in IA 20 will shed light on the pathways
leading to disease. Whether this locus or pathway will play a role in more common
forms of disease remains to be determined. However, once genes leading to IAs are
identified, they may better define the pathophysiology and natural history of aneurysm
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formation and rupture. Finally, these findings may contribute to improved diagnostic and
therapeutic approaches to this disease.

Environment
The management of cerebral aneurysms ≤ 7 mm remains a controversial issue in
neurosurgery. Numerous studies have outlined guidelines for treating unruptured
aneurysms that range from > 7 to 10 mm. However, despite the clinical observation that a
substantial number of IA ≤ 7mm also rupture, relatively little is known about the risk
factors associated with the rupture of these smaller aneurysms. In this study, we show for
the first time that among patients with aneurysms ≤ 7 mm, hypertension, younger age,
and posterior circulation are significant risk factors for rupture
We retrospectively analyzed aneurysm characteristics and social history
demographics of patients with both unruptured and ruptured aneurysms ≤ 7 mm. In our
study population, the average size of ruptured and unruptured aneurysms was 4.65 mm
and 4.33 mm, respectively. Consistent with published reports, the majority of ruptured
aneurysms ≤ 7 mm in our study were of the anterior circulation, mainly the anterior
communicating (ACoA) and middle cerebral arteries (MCA). In our unruptured
population, the majority of aneurysms were also of the anterior circulation (carotid and
middle cerebral arteries). Interestingly, however, posterior aneurysmal location conferred
substantially increased risk for IA rupture. Those whose aneurysms ruptured were more
likely to have poorly controlled hypertension.
Our findings extend those of previous retrospective reviews of aneurysmal rupture
risk. In particular, aneurysms ≤ 7 mm rupture and the majority of these aneurysms are of
the anterior circulation (16, 18-20, 33, 93) Interestingly, other studies, including the
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prospective arm of the ISUIA study, showed that aneurysms of the posterior circulation
were more likely to rupture at smaller sizes (≤ 7 mm) (15) However, based on a
comprehensive systematic review of the medical literature, we found no published data
meeting our liberal inclusion criteria for combination with our own data. Accordingly, to
the best of our knowledge, this study is the first to report on risk factors specifically
associated with the rupture of aneurysms less or equal to 7 mm in diameter.
A recent study analyzing 280 ruptured aneurysms showed that 74% were smaller
than 10mm, with a mean size of 7.6 mm (33) The mean size of ruptured aneurysms in
patients who were normotensive, had medically controlled hypertension, and had poorly
controlled hypertension were 8.3, 7.4, and 6.5mm, respectively. Furthermore, patients
with a family history of subarachnoid hemorrhage or who had poorly controlled
hypertension were more likely to have ruptured aneurysms less than 5mm. With respect
to location, ruptured aneurysms of the anterior communicating artery were smaller on
average (6.6 mm) than aneurysms in other locations. These results confirmed the results
of a previous single-center retrospective analysis that showed that 50% of ruptured
aneurysms were 6-10 mm in size and 35% were < 5 mm with the majority of small
aneurysms being of the anterior communicating artery (19)
The prospective arm of the ISUIA trial outlines the clearest guidelines indicating
treatment based on size and location of a small, unruptured aneurysm. This study stated
that the greatest benefit might be seen when aneurysms > 7 mm of the posterior
communicating artery are surgically treated in young patients (<50 years of age) (15)
The recommendation that aneurysms ≤ 7 mm of the anterior circulation in patients with
no family history of SAH should be left untreated was reinforced by others (32)
However, the limitation of these studies is the necessary reliance on 5-year or other
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relatively short-term durations of follow-up. Patients will be interested to know nearterm rupture risks, but SAH can occur following any time interval, making retrospective
study data essential for surgical decision-making.
Because the rupture of small aneurysms is a relatively rare event, it is difficult to
achieve a sample size that is large enough to detect modest risks for rupture. In this study,
the absence of a statistically significant relationship between such variables as number of
aneurysms, smoking, and family history of IA should be interpreted with caution. Type
II error (false negative) is a possible explanation, and further studies involving multiple
centers are warranted for the assembly of large, prospective cohorts with the power to
provide more precise estimates of the risk associated with these clinically important
variables. Additionally, as a chart review, we were limited in the direct quantification of
continuous variables. Data on pre-hemorrhage aneurysm size was inconsistent and often
unavailable in our patients presenting with SAH and therefore this data was excluded
from our analysis. This is another significant limitation of this study.
Based on our results, we suggest the need for new guidelines incorporating
relatively young age, hypertension, and posterior aneurysm location as possible factors
relevant to surgical management of IA ≤ 7 mm. These patients are at higher risk for
rupture, and have lower age-related surgical mortality and morbidity risks. These results
are consistent with those presented in the ISUIA prospective study, but add additional
clinically relevant information regarding the subset of patients with IA ≤ 7 mm.
Furthermore, more rigorous prospective studies with the specific aim of following
aneurysms less than or equal to 7mm are needed to justify these new sets of guidelines.
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CONCLUSION
Although the pathogenesis of intracranial aneurysm remains poorly understood,
there is significant evidence associating environmental and genetic factors with disease.
Size has long been considered the main risk factor for rupture; however, we demonstrate
that hypertension, posterior circulation, and relatively young age should also be
considered. In addition we identify 1p34.3-36.13 as a chromosomal region related to the
pathogenesis of IA. Although the literature is rich with linkage studies pointing to regions
throughout the genome, it appears that more than one locus will be involved in the IA
pathogenesis.
In short, it is likely that both locus and allelic heterogeneity along with
environmental factors play a role in IA pathogenesis complicating efforts at disease gene
identification. Certainly the identification of new genes important in IA pathogenesis will
provide insight into the primary determinants of this disease and will result in new
opportunities for early diagnosis in the preclinical setting. Identification of risk factors
related to formation and rupture of aneurysms will also assist in the understanding of
disease, while allowing clinicians the opportunity to modify treatment based upon risk.
Ultimately, it is anticipated that novel therapeutic strategies will be developed which will
target these newly elucidated genetic susceptibilities.
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APPENDIX

PATIENT INFORMATION SHEET
Name ______________________ Telephone # _______________________
Address ______________________________________________________
Date of birth __________ Race __________

Gender ________________

1. How old were you when your aneurysm / stroke was first diagnosed? ________
2. How many intracranial aneurysms did / do you have? _____________________
3. Did your aneurysm rupture and bleed? _________________________________
4. Did you have surgery to treat the aneurysm? Yes / No
- If yes, what was the date of surgery: _____________________________
Name of your neurosurgeon: _______________________________
Hospital where operation was performed: _____________________
5. Do you have high blood pressure: Yes / No When was it diagnosed? _______
- Please list the names of family members with high blood pressure?: _________
__________________________________________________________________
__________________________________________________________________
6. Have you ever smoked? Yes / No
- If yes, for how many years _______ How many packs a day? ________
7. Do you drink alcohol / beer / wine / liquor? Yes / No
- If yes, what do you drink? _____ How many drinks per day? ________
8. Please list any family members that have had an aneurysm or stroke?
(For example: cousins, nieces, nephews, grandchildren, grandparents, great aunts / uncles)

__________________________________________________________________
__________________________________________________________________
9. Please list any diseases that run in your family:
(Example stroke, high blood pressure, kidney disease, abdominal aneurysm AAA)
__________________________________________________________________
__________________________________________________________________
PLEASE SEND THIS FORM ALONG WITH THE BLOOD SAMPLES BY FED-EX
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